Abstract
Over three years following the discovery of the TAL code, artificial TAL effector DNA binding domains have emerged as the premier platform for building site-specific DNA binding polypeptides for use in biological research. Here, we provide an overview of TAL effector and alternative modular DNA binding domain (mDBD) technologies, focusing on their use in established and emerging architectures for building site-specific endonucleases for genome engineering applications. We also discuss considerations for choosing TAL effector/mDBD or alternative nuclease technologies for genome engineering projects ranging from basic laboratory gene editing of cultured cell lines to therapeutics. Finally, we highlight how the rapid pace of development of mDBD-based, such as monomeric TALENs (I-TevI-TAL), and more recently RNA-guided nucleases (CRISPR-Cas9) has led to a transition in the field of genome engineering towards development of the next generation of technologies aimed at controlling events that occur after targeted DNA breaks are made.
Keywords: DNA repair, double strand break, exonuclease, genome engineering, homing endonuclease, meganuclease, nuclease, TALEN, ZFN, zinc finger nuclease.
Current Gene Therapy
Title:Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies
Volume: 13 Issue: 4
Author(s): Andrew M. Scharenberg, Philippe Duchateau and Julianne Smith
Affiliation:
Keywords: DNA repair, double strand break, exonuclease, genome engineering, homing endonuclease, meganuclease, nuclease, TALEN, ZFN, zinc finger nuclease.
Abstract: Over three years following the discovery of the TAL code, artificial TAL effector DNA binding domains have emerged as the premier platform for building site-specific DNA binding polypeptides for use in biological research. Here, we provide an overview of TAL effector and alternative modular DNA binding domain (mDBD) technologies, focusing on their use in established and emerging architectures for building site-specific endonucleases for genome engineering applications. We also discuss considerations for choosing TAL effector/mDBD or alternative nuclease technologies for genome engineering projects ranging from basic laboratory gene editing of cultured cell lines to therapeutics. Finally, we highlight how the rapid pace of development of mDBD-based, such as monomeric TALENs (I-TevI-TAL), and more recently RNA-guided nucleases (CRISPR-Cas9) has led to a transition in the field of genome engineering towards development of the next generation of technologies aimed at controlling events that occur after targeted DNA breaks are made.
Export Options
About this article
Cite this article as:
Scharenberg M. Andrew, Duchateau Philippe and Smith Julianne, Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies, Current Gene Therapy 2013; 13 (4) . https://dx.doi.org/10.2174/15665232113139990026
DOI https://dx.doi.org/10.2174/15665232113139990026 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Cell Compatibility of an Eposimal Vector Mediated by the Characteristic Motifs of Matrix Attachment Regions
Current Gene Therapy Ethical Considerations in Conducting Pediatric and Neonatal Research in Clinical Pharmacology
Current Pharmaceutical Design Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Transcription Factors in Asthma: Are Transcription Factors a New Target for Asthma Therapy?
Current Drug Targets Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Copper Status Abnormalities and How to Measure Them in Neurodegenerative Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Dendritic Cells as A Conduit to Improve HIV Vaccines
Current Molecular Medicine Comparative Binding Mode and Residual Contribution from Lactoferrins (bLF and hLF) and HIV Gp120: An In silico Structural Perspective to Design Potent Peptide Inhibitor for HIV
Current Enzyme Inhibition Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
CNS & Neurological Disorders - Drug Targets Adiponectin in Asthma: Implications for Phenotyping
Current Protein & Peptide Science Adult Stem Cells and Extracellular Vesicles in Acute and Chronic Kidney Injury
Current Regenerative Medicine (Discontinued) Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets Nonalcoholic Fatty Liver Disease In Children: Recent Practice Guidelines, Where Do They Take Us?
Current Pediatric Reviews Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design